Radiotherapy in Prostate Cancer
Autor: | Kata Dabić Stanković, Ljiljana Radošević Jelić, Miodrag Aćimović, Tatjana Arsenijević |
---|---|
Rok vydání: | 2011 |
Předmět: |
Oncology
medicine.medical_specialty business.industry medicine.medical_treatment Disease medicine.disease law.invention Management of prostate cancer Radiation therapy Prostate cancer Randomized controlled trial Cancer control law Locally advanced disease Internal medicine medicine business Adjuvant |
Zdroj: | Prostate Cancer-Diagnostic and Therapeutic Advances |
DOI: | 10.5772/25784 |
Popis: | Therapeutic management of prostate cancer has become complex, multidisciplinary and stage-specific. (Heidenereich et al., 2011) Based on PSA level, histopathological grading and clinical staging, prostate cancer is classified as low-, intermediateand high risk for disease recurrence. The risk status often plays a major role in deciding further therapy. (Kirby & Madhavan, 2010) It is usually impossible to state that one therapy is superior to another because of the lack of randomized controlled trials. However some recommendations can be made. (Heidenereich et al., 2011, Aus et al. 2001) Based on European Association of Urology recommendations in 2010, patients with low-risk (PSA ≤10 ng/ml, Gleason score 20ng/ml, Gleason score 8-10 or ≥cT3a) (Heidenereich et al., 2011, Choe & Liauw, 2010). Radiotherapy is widely used as curative treatment modality for prostate cancer. There is a diverse array of radiotherapeutic strategies that can be effectively used to treat both organconfined and locally advanced disease, alone or in combination with androgen-deprivation therapy. Furthermore, it has also a significant role in post-prostatectomy setting, as adjuvant or salvage radiotherapy. In recent decades, radiotherapy in prostate cancer has undergone significant clinical and technological advances that aim to optimize cancer control outcomes while minimizing treatment morbidity. (Choe & Liauw, 2010, Hayden et al., 2010) |
Databáze: | OpenAIRE |
Externí odkaz: |